Cargando…
Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016402/ https://www.ncbi.nlm.nih.gov/pubmed/33812495 http://dx.doi.org/10.1016/S1470-2045(21)00155-8 |
| _version_ | 1783673853842554880 |
|---|---|
| author | Waissengrin, Barliz Agbarya, Abed Safadi, Esraa Padova, Hagit Wolf, Ido |
| author_facet | Waissengrin, Barliz Agbarya, Abed Safadi, Esraa Padova, Hagit Wolf, Ido |
| author_sort | Waissengrin, Barliz |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8016402 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80164022021-04-02 Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors Waissengrin, Barliz Agbarya, Abed Safadi, Esraa Padova, Hagit Wolf, Ido Lancet Oncol Comment Elsevier Ltd. 2021-05 2021-04-01 /pmc/articles/PMC8016402/ /pubmed/33812495 http://dx.doi.org/10.1016/S1470-2045(21)00155-8 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Waissengrin, Barliz Agbarya, Abed Safadi, Esraa Padova, Hagit Wolf, Ido Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors |
| title | Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors |
| title_full | Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors |
| title_fullStr | Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors |
| title_full_unstemmed | Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors |
| title_short | Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors |
| title_sort | short-term safety of the bnt162b2 mrna covid-19 vaccine in patients with cancer treated with immune checkpoint inhibitors |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016402/ https://www.ncbi.nlm.nih.gov/pubmed/33812495 http://dx.doi.org/10.1016/S1470-2045(21)00155-8 |
| work_keys_str_mv | AT waissengrinbarliz shorttermsafetyofthebnt162b2mrnacovid19vaccineinpatientswithcancertreatedwithimmunecheckpointinhibitors AT agbaryaabed shorttermsafetyofthebnt162b2mrnacovid19vaccineinpatientswithcancertreatedwithimmunecheckpointinhibitors AT safadiesraa shorttermsafetyofthebnt162b2mrnacovid19vaccineinpatientswithcancertreatedwithimmunecheckpointinhibitors AT padovahagit shorttermsafetyofthebnt162b2mrnacovid19vaccineinpatientswithcancertreatedwithimmunecheckpointinhibitors AT wolfido shorttermsafetyofthebnt162b2mrnacovid19vaccineinpatientswithcancertreatedwithimmunecheckpointinhibitors |